Reboxetine is a drug used for the acute treatment of major depression and for maintenance therapy of depression. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra.
- Mechanism
- Curator reviewed
Reboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake in vitro to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboxetine does not affect dopamine or serotonin reuptake and it has low in vivo and in vitro affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors.
- Primary indication
- For the treatment of clinical depression.Curator reviewed · 2 structured indications
- Formula / weight
- C19H23NO3 · 313.397 g/mol (avg)
Resolves to
CBQGYUDMJHNJBX-RTBURBONSA-NSMILES[H][C@@]1(CNCCO1)[C@H](OC1=CC=CC=C1OCC)C1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Reboxetine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account